Nadroparin calcium

Nadroparin calcium

Clinical data
Trade names	Fraxiparin(e), Fraxodi, others
AHFS/Drugs.com	International Drug Names
Routes of administration	Subcutaneous injection (except for haemodialysis)
ATC code	B01AB06 (WHO)
Legal status
Legal status	AU: S4 (Prescription only)Template:Infobox drug/non-ref-space CA: ℞-onlyTemplate:Infobox drug/non-ref-space
Pharmacokinetic data
Bioavailability	89% (SC dose)
Elimination half-life	3.7 hours (SC dose)
Excretion	clearance 21.4mL/min (+/- 7)
Identifiers
IUPAC name (4S,6R)-6-[(2R,4R)-4,6-dihydroxy-5-(sulfonatoamino)-2-(sulfonatooxymethyl)oxan-3-yl]oxy-3,4-dihydroxy-5-sulfonatooxyoxane-2-carboxylate
CAS Number	Template:Infobox drug/formatCASnumber Template:Infobox drug/formatCASnumber
PubChem CID	Template:Infobox drug/formatPubChemCID Template:Infobox drug/formatPubChemCID
PubChem SID	Template:Infobox drug/formatPubChemSID Template:Infobox drug/formatPubChemSID
IUPHAR/BPS	Template:Infobox drug/formatIUPHARBPS Template:Infobox drug/formatIUPHARBPS
DrugBank	Template:Infobox drug/formatDrugBank Template:Infobox drug/formatDrugBank
ChemSpider	Template:Infobox drug/formatChemSpider Template:Infobox drug/formatChemSpider
UNII	Template:Infobox drug/formatUNII Template:Infobox drug/formatUNII
KEGG	Template:Infobox drug/formatKEGG Template:Infobox drug/formatKEGG
ChEBI	Template:Infobox drug/formatChEBI Template:Infobox drug/formatChEBI
ChEMBL	Template:Infobox drug/formatChEMBL Template:Infobox drug/formatChEMBL
NIAID ChemDB	Template:Infobox drug/formatChemDBNIAID Template:Infobox drug/formatChemDBNIAID
PDB ligand	Template:Infobox drug/formatPDBligand Template:Infobox drug/formatPDBligand
CompTox Dashboard (EPA)	Template:Infobox drug/formatCompTox Template:Infobox drug/formatCompTox
Chemical and physical data
Molar mass	4300 g/mol
3D model (JSmol)	Template:Infobox drug/formatJmol Template:Infobox drug/formatJmol
Data page
Template:Infobox drug/data page link
☒NcheckY (what is this?)  (verify)

Nadroparin (trade names Fraxiparin[e], Fraxodi, among others) is an anticoagulant belonging to a class of drugs called low molecular weight heparins (LMWHs). Nadroparin was developed by Sanofi-Synthélabo.

Nadroparin is used in general and orthopedic surgery to prevent thromboembolic disorders (deep vein thrombosis and pulmonary embolism), and as treatment for deep vein thrombosis. It is also used to prevent clotting during hemodialysis, and for treatment of unstable angina and non-Q wave myocardial infarction.

For the treatment and prevention of DVT, the drug is administered as a subcutaneous injection (under the skin), usually around the abdomen. It is on the World Health Organization's List of Essential Medicines.

External links

• "NCI Drug Dictionary". National Cancer Institute. 2 February 2011. Retrieved 2 April 2019.

• File:Fraxiparine 0,6 ml injection.jpg

  Fraxiparine 0,6 ml injection, containing nadroparin calcium

  Shafiq N, Malhotra S, Pandhi P, Sharma N, Bhalla A, Grover A (2006). "A randomized controlled clinical trial to evaluate the efficacy, safety, cost-effectiveness and effect on PAI-1 levels of the three low-molecular-weight heparins--enoxaparin, nadroparin and dalteparin. The ESCAPe-END study". Pharmacology. 78 (3): 136–43. doi:10.1159/000096484. PMID 17057417. S2CID 95878036.

Template:Asbox